Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 685

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Drug-Coated Balloon Versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease: 12-Month Results From the IN.PACT SFA Randomized Trial

Open access
Tepe, Gunnar, Laird, John, Schneider, Peter, Brodmann, Marianne, Krishnan, Prakash, Micari, Antonio, Metzger, Christopher, Scheinert, Dierk, Zeller, Thomas, Cohen, David J., Snead, David B., Alexander, Beaux, Landini, Mario, Jaff, Michael R.·2015·Circulation

Abstract

Background—: Drug-coated balloons (DCBs) have shown promise in improving the outcomes for patients with peripheral artery disease. We compared a paclitaxel-coated balloon with percutaneous transluminal angioplasty (PTA) for the treatment of symptomatic superficial femoral and popliteal artery disease. Methods and Results—: The IN.PACT SFA Trial is a prospective, multicenter, single-blinded, randomized trial in which 331 patients with intermittent claudication or ischemic rest pain attributable to superficial femoral and popliteal peripheral artery disease were randomly assigned in a 2:1 ratio to treatment with DCB or PTA. The primary efficacy end point was primary patency, defined as freedom from restenosis or clinically driven target lesion revascularization at 12 months. Baseline characteristics were similar between the 2 groups. Mean lesion length and the percentage of total occlusions for the DCB and PTA arms were 8.94±4.89 and 8.81±5.12 cm ( P =0.82) and 25.8% and 19.5% ( P =0.22), respectively. DCB resulted in higher primary patency versus PTA (82.2% versus 52.4%; P <0.001). The rate of clinically driven target lesion revascularization was 2.4% in the DCB arm in comparison with 20.6% in the PTA arm ( P <0.001). There was a low rate of vessel thrombosis in both arms (1.4% after DCB and 3.7% after PTA [ P =0.10]). There were no device- or procedure-related deaths and no major amputations. Conclusions—: In this prospective, multicenter, randomized trial, DCB was superior to PTA and had a favorable safety profile for the treatment of patients with symptomatic femoropopliteal peripheral artery disease. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique Identifiers: NCT01175850 and NCT01566461.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.114.011004

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 685

Metadata

Authors
Tepe, G., Laird, J., Schneider, P., Brodmann, M., Krishnan, P., Micari, A., Metzger, C., Scheinert, D., Zeller, T., Cohen, D. J., Snead, D. B., Alexander, B., Landini, M., & Jaff, M. R.
Venue
Circulation
Published
2015-02-03
Volume
131
Issue
5
Pages
495-502
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W1977671695
Cited by
685
References
19
FWCI
51.97
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Drug-Coated Balloon Versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease: 12-Month Results From the IN.PACT SFA Randomized Trial. https://app.cochat.ai/papers/10.1161/circulationaha.114.011004
The paper
Tepe, G., Laird, J., Schneider, P., Brodmann, M., Krishnan, P., Micari, A., Metzger, C., Scheinert, D., Zeller, T., Cohen, D. J., Snead, D. B., Alexander, B., Landini, M., & Jaff, M. R. (2015). Drug-Coated Balloon Versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease: 12-Month Results From the IN.PACT SFA Randomized Trial. Circulation. https://doi.org/10.1161/circulationaha.114.011004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.